Focused Ultrasound Therapy
The FDA has approved Profound Medical’s Sonalleve device for the treatment of patients with Osteoid Osteoma. For more information on treatment site locations, please see Profound Medical’s website.
Focused ultrasound is an early-stage, noninvasive, therapeutic technology with the potential to improve the quality of life and decrease the cost of care for patients with osteoid osteoma. This novel technology focuses beams of ultrasound energy precisely and accurately on targets deep in the body without damaging surrounding normal tissue.
How it Works
Where the beams converge, focused ultrasound produces precise ablation (thermal destruction of tissue) enabling osteoid osteoma to be treated without surgery.
The primary options for treatment of osteoid osteoma include pain medications, but some cases require invasive surgery.
For certain patients, focused ultrasound could provide a noninvasive alternative to surgery with less risk of complications – such as surgical wound healing or infection – at a lower cost. It can reach the desired target without damaging surrounding tissue and is repeatable, if necessary.
A study has opened at the University of California in San Francisco (UCSF) and Stanford University, which is comparing MR-guided focused ultrasound treatment for osteoid osteoma to radiofrequency ablation.
A study assessed MR-guided focused ultrasound to treat osteoid osteoma at The Hospital for Sick Children (SickKids) in Toronto, Canada. Publication of the results is expected soon.
A registry, funded in part by the Foundation, has begun and will enroll more patients at additional sites worldwide. For more information, contact Simal Goman at 416-813-6456 or .
There is a clinical trial that has completed recruitment at Children's National Medical Center in Washington, DC. We are awaiting publication of the results.
For a full list of osteoid osteoma clinical trials, please see here.
Regulatory Approval and Reimbursement
Chongqing Haifu Medical Technology is approved for osteoid osteoma in Europe, Russia and China. The Insightec ExAblate Neuro is approved for treating this condition in Europe.
To date, focused ultrasound is not widely reimbursed by medical insurers for treatment of osteoid osteoma.
Arrigoni F, Spiliopoulos S, de Cataldo C, Reppas L, Palumbo P, Mazioti A, Bruno F, Zugaro L, Papakonstantinou O, Barile A, Kelekis A, Masciocchi C, Filippiadis D. A bicentric propensity score matching study comparing percutaneous computed tomography-guided radiofrequency Ablation to Magnetic Resonance-guided Focused Ultrasounds for the treatment of osteoid osteoma. J Vasc Interv Radiol. 2021 Mar 25:S1051-0443(21)00932-5. doi: 10.1016/j.jvir.2021.03.528.
Arrigoni F, Bruno F, Gianneramo C, Palumbo P, Zugaro L, Zoccali C, Barile A, Masciocchi C. Evolution of the imaging features of osteoid osteoma treated with RFA or MRgFUS during a long-term follow-up: a pictorial review with clinical correlations. Radiol Med. 2020 Feb 10. doi: 10.1007/s11547-020-01134-w.
Arrigoni F, Napoli A, Bazzocchi A, Zugaro L, Scipione R, Bruno F, Palumbo P, Anzidei M, Mercatelli D, Gravina GL, Zoccali C, Ghanouni P, Barile A, Catalano C, Masciocchi C. Magnetic-resonance-guided focused ultrasound treatment of non-spinal osteoid osteoma in children: multicentre experience. Pediatr Radiol. 2019 May 25. doi: 10.1007/s00247-019-04426-0. [Epub ahead of print] PMID: 31129699
Scipione R, Anzidei M, Bazzocchi A, Gagliardo C, Catalano C, Napoli A. HIFU for Bone Metastases and other Musculoskeletal Applications. Semin Intervent Radiol. 2018 Oct;35(4):261-267. doi: 10.1055/s-0038-1673363. Epub 2018 Nov 5.
Bing F, Vappou J, de Mathelin M, Gangi A. Targetability of osteoid osteomas and bone metastases by MR-guided high intensity focused ultrasound (MRgHIFU). Int J Hyperthermia. 2018 Sep 13:1-9. doi: 10.1080/02656736.2018.1508758.
Yarmolenko PS, Eranki A, Partanen A, Celik H, Kim A, Oetgen M, Beskin V, Santos D, Patel J, Kim PCW, Sharma K. Technical aspects of osteoid osteoma ablation in children using MR-guided high intensityfocussed ultrasound. Int J Hyperthermia. 2018 Feb;34(1):49-58. doi: 10.1080/02656736.2017.1315458. Epub 2017 Apr 24.
Hudson TJ, Looi T, Pichardo S, Amaral J, Temple M, Drake JM, Waspe AC. Simulating thermal effects of MR-guided focused ultrasound in cortical bone and its surrounding tissue. Med Phys. 2018 Feb;45(2):506-519. doi: 10.1002/mp.12704. Epub 2017 Dec 25.
Napoli A, Bazzocchi A, Scipione R, Anzidei M, Saba L, Ghanouni P, Cozzi DA, Catalano C. Noninvasive Therapy for Osteoid Osteoma: A Prospective Developmental Study with MR Imaging-guided High-Intensity Focused Ultrasound. Radiology. 2017 Oct;285(1):186-196. doi: 10.1148/radiol.2017162680. Epub 2017 Jun 7.
Sharma KV, Yarmolenko PS, Celik H, Eranki A, Partanen A, Smitthimedhin A, Kim A, Oetgen M, Santos D, Patel J, Kim P. Comparison of Noninvasive High-Intensity Focused Ultrasound with Radiofrequency Ablation of Osteoid Osteoma. J Pediatr. 2017 Aug 11. pii: S0022-3476(17)30896-X. doi: 10.1016/j.jpeds.2017.06.046.
Arrigoni F, Barile A, Zugaro L, Splendiani A, Di Cesare E, Caranci F, Ierardi AM, Floridi C, Angileri AS, Reginelli A, Brunese L, Masciocchi C. Intra-articular benign bone lesions treated with Magnetic Resonance-guided Focused Ultrasound (MRgFUS): imaging follow-up and clinical results. Med Oncol. 2017 Apr;34(4):55. doi: 10.1007/s12032-017-0904-7. Epub 2017 Feb 27.
Rovella MS, Martins GL, Cavalcanti CF, Bor-Seng-Shu E, Camargo OP, Cerri GG, Menezes MR. Magnetic Resonance-Guided High-Intensity Focused Ultrasound Ablation of Osteoid Osteoma: A Case Series Report. Ultrasound Med Biol. 2016 Apr;42(4):919-23. doi: 10.1016/j.ultrasmedbio.2015.11.003. Epub 2016 Jan 16.
Masciocchi C, Zugaro L, Arrigoni F, Gravina GL, Mariani S, La Marra A, Zoccali C, Flamini S, Barile A. Radiofrequency ablation versus magnetic resonance guided focused ultrasound surgery for minimally invasive treatment of osteoid osteoma: a propensity score matching study. Eur Radiol. 2015 Nov 26.
Click here for additional references from PubMed.